One-sentence summary of key findings: INNOVATE Corp. (VATE) is a diversified holding company whose Infrastructure segment (primarily DBM Global) delivered strong Q2 2026 revenue growth and a swing to profitability, supported by recent regulatory approvals for its Life Sciences subsidiary MediBeacon's kidney function monitoring technology, amid a history of name changes, segment refocusing, persistent net losses on a trailing basis, high stock volatility, and sparse analyst coverage.
INNOVATE Corp., through subsidiaries, operates in three main segments: Infrastructure (structural steel fabrication, erection, and industrial construction services via DBM Global), Life Sciences (medical/aesthetic technologies including MediBeacon's transdermal GFR system and R2's Glacial Skin), and Spectrum (over-the-air broadcasting stations across the US). The company was incorporated in 1994, formerly known as HC2 Holdings, Inc., and rebranded to INNOVATE Corp. in September 2021 to emphasize its "new economy" focus; it is headquartered in New York, NY, with approximately 3,700-3,738 full-time employees and a fiscal year ending December 31.
The rebranding and segment emphasis suggest a strategic shift toward higher-growth areas like life sciences, though infrastructure remains the primary revenue driver.
Yahoo Finance Company Profile | Company Website | Investor Relations
Data limitations: All financial and performance figures are based on publicly reported data as of the most recent filings and summaries available around early August 2026 (e.g., TTM or FY2025/2026 periods). Historical monthly closes are approximate from Yahoo Finance archives and subject to adjustments (e.g., splits/dividends). No current or intraday prices are included. Stock is highly volatile with beta ~2.37 (5Y monthly).
| Period | VATE Return | S&P 500 Return |
|---|---|---|
| YTD | +155.53% | +13.14% |
| 1-Year | +153.85% | +22.16% |
| 3-Year | +23.00% | +71.41% |
| 5-Year | +70.16% | +74.57% |
52-week range (from reports): approximately $3.75 low to $21.30 high. Strong recent outperformance may reflect positive news flow from MediBeacon approvals and infrastructure demand, but longer-term underperformance vs. benchmark highlights volatility and past challenges. Future performance uncertain due to execution risks in life sciences commercialization and debt levels.
Yahoo Finance Historical Data | MarketWatch Charts
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $1.34B | Primary driver: Infrastructure segment |
| Net Income (TTM, to common) | -$56.4M | Profit margin -3.96% |
| Diluted EPS (TTM) | -$4.24 | Negative due to losses |
| Total Cash (most recent quarter) | $134.6M | Liquidity position |
| Return on Assets (TTM) | 2.44% | Positive despite net loss |
| Levered Free Cash Flow (TTM) | $139.55M | Positive cash generation |
| Metric | Q2 2026 | YoY Change |
|---|---|---|
| Consolidated Revenue | $421.6M | +74.2% |
| Adjusted EBITDA | $46.3M | +194.9% |
| Net Income (to common/preferred) | +$10.4M | From -$22.0M loss |
FY2025 revenue reported around $1.25B in some summaries with net loss ~$60.6M. Q2 swing to profit suggests improving operational leverage in infrastructure, potentially aided by project demand (e.g., AI-related). Sustainability of profitability unclear given historical losses and segment mix.
Yahoo Finance Financials | INNOVATE IR Earnings Releases & Presentations | SEC Filings (10-K/10-Q)
Data limitations and uncertainties: Analyst coverage is very limited/sparse (often 0-7 analysts mentioned across sources, with conflicting summaries). Ratings and targets should be interpreted cautiously as they may not reflect broad consensus or recent developments. Data as of searches around Aug 2026.
Divergent ratings may stem from differing views on life sciences upside versus infrastructure cyclicality and balance sheet risks. With minimal coverage, ratings are not reliable predictors; investors should review primary filings directly.
MarketBeat Analyst Ratings | Yahoo Finance Analyst Estimates
Specific major customers are not publicly detailed in aggregated sources (typical for holding companies with subsidiary operations). Infrastructure likely serves commercial, industrial, and infrastructure projects (e.g., buildings, bridges, power plants, refineries); Spectrum serves OTA broadcast viewers and advertisers; Life Sciences targets medical/aesthetic markets (e.g., kidney diagnostics, skin treatments). Exact customer concentration or contracts unknown without subsidiary-level disclosures.
Peers identified in infrastructure/engineering & construction space include Fluor Corp., Quanta Services, Matrix Service Company (MTRX), Broadwind Inc., NWPX Infrastructure, ESCO Technologies, and others like Granite Construction.
| Competitor | Focus Area | Notes |
|---|---|---|
| Quanta Services (PWR) | Infrastructure/Engineering | Larger scale, multi-billion backlog |
| Fluor (FLR) | Engineering & Construction | Global projects, stronger balance sheet |
| Matrix Service (MTRX) | Industrial Construction | Similar services |
| Broadwind (BWEN) | Industrial Components | Steel/fabrication overlap |
VATE's smaller scale and diversified (non-pure-play) structure may differentiate it but also expose it to holding company complexities vs. focused peers.
Additional Notes on Data Limitations/Assumptions: All information synthesized from public web sources (Yahoo Finance, company IR, SEC mentions, news aggregators) as of ~August 7, 2026. Financials and performance are trailing/reported figures and may be revised in future filings. Analyst data is particularly sparse and inconsistent across platforms. No investment advice implied; always verify with primary sources like 10-K/10-Q and consult professionals. Stock performance excludes dividends unless noted in totals.